0001437749-22-023679.txt : 20221005
0001437749-22-023679.hdr.sgml : 20221005
20221005164043
ACCESSION NUMBER: 0001437749-22-023679
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221003
FILED AS OF DATE: 20221005
DATE AS OF CHANGE: 20221005
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: NOUGUES MAXIMO F
CENTRAL INDEX KEY: 0001758507
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35703
FILM NUMBER: 221296156
MAIL ADDRESS:
STREET 1: C/O PUMA BIOTECHNOLOGY, INC.
STREET 2: 10880 WILSHIRE BOULEVARD, SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: PUMA BIOTECHNOLOGY, INC.
CENTRAL INDEX KEY: 0001401667
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770683487
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
BUSINESS PHONE: (424) 248-6500
MAIL ADDRESS:
STREET 1: 10880 WILSHIRE BLVD.
STREET 2: SUITE 2150
CITY: LOS ANGELES
STATE: CA
ZIP: 90024
FORMER COMPANY:
FORMER CONFORMED NAME: INNOVATIVE ACQUISITIONS CORP
DATE OF NAME CHANGE: 20070601
4
1
rdgdoc.xml
FORM 4
X0306
4
2022-10-03
0001401667
PUMA BIOTECHNOLOGY, INC.
PBYI
0001758507
NOUGUES MAXIMO F
C/O PUMA BIOTECHNOLOGY, INC.
10880 WILSHIRE BLVD., SUITE 2150
LOS ANGELES
CA
90024
1
Chief Financial Officer
Common Stock
2022-10-03
4
S
0
165
2.3354
D
111248
D
The sales reported in this Form 4 were to satisfy tax obligations in connection with the vesting of restricted stock units in accordance with the Company's mandatory sale to cover taxes program.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.33 to $2.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.
/s/ Gordon Esplin as attorney-in-fact for Maximo F. Nougues
2022-10-05